Loss of heterozygosity analysis: Practically and conceptually flawed?

被引:61
作者
Tomlinson, IPM [1 ]
Lambros, MBK [1 ]
Roylance, RR [1 ]
机构
[1] Imperial Canc Res Fund, Mol & Populat Genet Lab, London WC2A 3PX, England
关键词
D O I
10.1002/gcc.10085
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Knudson "two-hit" hypothesis has provided the rationale for studies that aim to identify tumor-suppressor genes by mapping regions of allelic loss (loss of heterozygosity, LOH). Although LOH has been found in practically all types of tumors, very few such projects have been successful in identifying their tumor-suppressor targets. The prime explanation for this failure is probably that researchers have, in general, been too credulous about the two-hit hypothesis, and too willing to ignore factors such as intratumor heterogeneity, contamination by normal cells, karyotypic complexity, homozygous deletions, gene dosage changes, and polymerase chain reaction artifacts. We suggest ways of minimizing these problems. Unfortunately, there is no guarantee that existing or newer methods, such as genomic microarrays and in situ single-nucleotide polymorphism analysis, will solve the difficulties of LOH analysis. The future prospects for LOH studies are, as ever, uncertain. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:349 / 353
页数:5
相关论文
共 26 条
[1]   Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement [J].
Abdel-Rahman, WM ;
Katsura, K ;
Rens, W ;
Gorman, PA ;
Sheer, D ;
Bicknell, D ;
Bodmer, WF ;
Arends, MJ ;
Wyllie, AH ;
Edwards, PAW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) :2538-2543
[2]  
Bonsing BA, 2000, GENE CHROMOSOME CANC, V28, P173, DOI 10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO
[3]  
2-1
[4]   High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH [J].
Bruder, CEG ;
Hirvelä, C ;
Tapia-Paez, I ;
Fransson, I ;
Segraves, R ;
Hamilton, G ;
Zhang, XX ;
Evans, DG ;
Wallace, AJ ;
Baser, ME ;
Zucman-Rossi, J ;
Hergersberg, M ;
Boltshauser, E ;
Papi, L ;
Rouleau, GA ;
Poptodorov, G ;
Jordanova, A ;
Rask-Andersen, H ;
Kluwe, L ;
Mautner, V ;
Sainio, M ;
Hung, G ;
Mathiesen, T ;
Möller, C ;
Pulst, SM ;
Harder, H ;
Heiberg, A ;
Honda, M ;
Miimura, M ;
Sahlén, S ;
Blennow, E ;
Albertson, DG ;
Pinkel, D ;
Dumanski, JP .
HUMAN MOLECULAR GENETICS, 2001, 10 (03) :271-282
[5]   Epigenetic inactivation of RASSF14 in lung and breast cancers and malignant phenotype suppression [J].
Burbee, DG ;
Forgacs, E ;
Zöchbauer-Müller, S ;
Shivakumar, L ;
Fong, K ;
Gao, BN ;
Randle, D ;
Kondo, M ;
Virmani, A ;
Bader, S ;
Sekido, Y ;
Latif, F ;
Milchgrub, S ;
Toyooka, S ;
Gazdar, AF ;
Lerman, MI ;
Zabarovsky, E ;
White, M ;
Minna, JD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :691-699
[6]   Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms [J].
Calin, GA ;
di Iasio, MG ;
Caprini, E ;
Vorechovsky, I ;
Natali, PG ;
Sozzi, G ;
Croce, CM ;
Barbanti-Brodano, G ;
Russo, G ;
Negrini, M .
ONCOGENE, 2000, 19 (09) :1191-1195
[7]  
Cleton-Jansen AM, 2001, CANCER RES, V61, P1171
[8]   Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 [J].
Dammann, R ;
Li, C ;
Yoon, JH ;
Chin, PL ;
Bates, S ;
Pfeifer, GP .
NATURE GENETICS, 2000, 25 (03) :315-319
[9]   BREAST-CANCER GENETIC EVOLUTION .1. DATA FROM CYTOGENETICS AND DNA CONTENT [J].
DUTRILLAUX, B ;
GERBAULTSEUREAU, M ;
REMVIKOS, Y ;
ZAFRANI, B ;
PRIEUR, M .
BREAST CANCER RESEARCH AND TREATMENT, 1991, 19 (03) :245-255
[10]  
Forozan F, 2000, CANCER RES, V60, P4519